# EDGAR Filing Document

**Accession Number:** 0001816581
**File Stem:** 0001628280-26-030722
**Filing Date:** 2026-5
**Character Count:** 157631
**Document Hash:** 548dad391d333915d40556f9264cc039
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-030722.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001628280-26-030722

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 86

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ouster, Inc.
- **CENTRAL INDEX KEY:** 0001816581
- **STANDARD INDUSTRIAL CLASSIFICATION:** GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC [3569]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39463
- **FILM NUMBER:** 26944525

**BUSINESS ADDRESS:**
- **STREET 1:** 350 TREAT AVENUE
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94110
- **BUSINESS PHONE:** (415) 987-6972

**MAIL ADDRESS:**
- **STREET 1:** 350 TREAT AVENUE
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Colonnade Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200701

?xml version='1.0' encoding='ASCII'? oust-20260331

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

_______________________

**FORM 10-Q** 

_______________________

(Mark One)

&nbsp;&nbsp;&nbsp;&nbsp;☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to

Commission File Number: 001-39463

_______________________

**Ouster, Inc.** 

**(Exact name of registrant as specified in its charter)** 

_______________________

---

| | |
|:---|:---|
| **Delaware** | **86-2528989** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**350 Treat Avenue**

**San Francisco, California 94110**

**(Address of principal executive offices) (Zip Code)**

**(415) 949-0108** 

**(Registrant's telephone number, including area code)** 

**N/A**

**(Former name, former address, and former fiscal year, if changed since last report)** 

_______________________

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| **Common stock, $0.0001 par value per share** | **OUST** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒ &nbsp;&nbsp;&nbsp;&nbsp;No ☐

&nbsp;&nbsp;&nbsp;&nbsp;

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

&nbsp;&nbsp;&nbsp;&nbsp;

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 1, 2026, the registrant had 63,672,949 shares of common stock, $0.0001 par value per share, outstanding.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| | **[Part I - Financial Information](#i105426b996a349fab16c7184348567c3_13)** | |
| <u>[Item 1.](#i105426b996a349fab16c7184348567c3_16)</u> | <u>[Financial Statements](#i105426b996a349fab16c7184348567c3_16)</u> | [5](#i105426b996a349fab16c7184348567c3_16) |
| | <u>[Condensed Consolidated Balance Sheets (Unaudited)](#i105426b996a349fab16c7184348567c3_19)</u> | [5](#i105426b996a349fab16c7184348567c3_19) |
| | <u>[Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)](#i105426b996a349fab16c7184348567c3_22)</u> | [6](#i105426b996a349fab16c7184348567c3_22) |
| | <u>[Condensed Consolidated Statements of Stockholders' Equity (Unaudited)](#i105426b996a349fab16c7184348567c3_25)</u> | [7](#i105426b996a349fab16c7184348567c3_25) |
| | <u>[Condensed Consolidated Statements of Cash Flows (Unaudited)](#i105426b996a349fab16c7184348567c3_31)</u> | [8](#i105426b996a349fab16c7184348567c3_31) |
| | <u>[Notes to](#i105426b996a349fab16c7184348567c3_34)[Condensed](#i105426b996a349fab16c7184348567c3_34)[Consolidated Financial Statement](#i105426b996a349fab16c7184348567c3_34)[s (Unaudited)](#i105426b996a349fab16c7184348567c3_34)</u> | [9](#i105426b996a349fab16c7184348567c3_34) |
| <u>[Item 2.](#i105426b996a349fab16c7184348567c3_127)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i105426b996a349fab16c7184348567c3_127)</u> | [28](#i105426b996a349fab16c7184348567c3_127) |
| <u>[Item 3.](#i105426b996a349fab16c7184348567c3_151)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i105426b996a349fab16c7184348567c3_151)</u> | [38](#i105426b996a349fab16c7184348567c3_151) |
| <u>[Item 4.](#i105426b996a349fab16c7184348567c3_154)</u> | <u>[Controls and Procedures](#i105426b996a349fab16c7184348567c3_154)</u> | [39](#i105426b996a349fab16c7184348567c3_154) |
| | **Part II - Other Information** | |
| <u>[Item 1.](#i105426b996a349fab16c7184348567c3_160)</u> | <u>[Legal Proceedings](#i105426b996a349fab16c7184348567c3_160)</u> | [40](#i105426b996a349fab16c7184348567c3_160) |
| <u>[Item 1A.](#i105426b996a349fab16c7184348567c3_163)</u> | <u>[Risk Factors](#i105426b996a349fab16c7184348567c3_163)</u> | [40](#i105426b996a349fab16c7184348567c3_163) |
| <u>[Item 2.](#i105426b996a349fab16c7184348567c3_166)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i105426b996a349fab16c7184348567c3_166)</u> | [40](#i105426b996a349fab16c7184348567c3_166) |
| <u>[Item 3.](#i105426b996a349fab16c7184348567c3_169)</u> | <u>[Defaults Upon Senior Securities](#i105426b996a349fab16c7184348567c3_169)</u> | [40](#i105426b996a349fab16c7184348567c3_169) |
| <u>[Item 4.](#i105426b996a349fab16c7184348567c3_172)</u> | <u>[Mine Safety Disclosures](#i105426b996a349fab16c7184348567c3_172)</u> | [40](#i105426b996a349fab16c7184348567c3_175) |
| <u>[Item 5.](#i105426b996a349fab16c7184348567c3_175)</u> | <u>[Other Information](#i105426b996a349fab16c7184348567c3_175)</u> | [40](#i105426b996a349fab16c7184348567c3_175) |
| <u>[Item 6.](#i105426b996a349fab16c7184348567c3_181)</u> | <u>[Exhibits](#i105426b996a349fab16c7184348567c3_181)</u> | [41](#i105426b996a349fab16c7184348567c3_181) |
| <u>[Signature](#i105426b996a349fab16c7184348567c3_184)</u> | <u>[Signature](#i105426b996a349fab16c7184348567c3_184)</u> | [42](#i105426b996a349fab16c7184348567c3_184) |

---

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

*This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Ouster, Inc. (the "Company", "Ouster," or "we") intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this Quarterly Report other than statements of historical fact, including, without limitation, statements regarding: expected contractual obligations and capital expenditures; the capabilities of and demand for Ouster's products; Ouster's anticipated new product launches and developments, including software-related solutions systems, and the timing for those launches and developments; the anticipated benefits and synergies of strategic transactions, including the Stereolabs acquisition, and expected integration efforts; the impact to f tariffs and trade policy actions on Ouster's costs, supply chain, and customer demand; Ouster's ability to grow its sales and marketing organization; Ouster's future results of operations, cash reserve and financial position; projected industry and business trends; the remediation of material weaknesses; potential risks of inventory obsolescence; Ouster's future business strategy, plans, distribution partnerships, market growth and its objectives for future operations, including executing towards profitability; Ouster's competitive market position within its industry and the impact of market conditions and other macroeconomic factors on Ouster's business, financial condition and results of operation, foreign currency exchange rate fluctuations and the effectiveness of hedging activities, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "could," "would," "project," "plan," "potentially," "preliminary," "likely," "aim," "forecast," "should," "can have," and similar expressions are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties, and assumptions that may cause actual results to differ materially from those that Ouster expected, including, but not limited to*, *Ouster's limited operating history and history of losses; substantial research and development costs needed to develop and commercialize new products; Ouster's ability to overcome its limited sales history and establish and maintain confidence in its long-term business prospects; fluctuations in its operating results; Ouster's ability to maintain competitive average selling prices or high sales volumes or reduce product costs; conditions in its customers' industries; the competitive environment in which Ouster operates; the negotiating power and product standards of its customers; the inclusion of its products in target markets; the creditworthiness of Ouster's customers; the ability of its lidar technology roadmap and new software solutions to catalyze growth; the selection of Ouster's products for inclusion in target markets; risks of product delivery problems or defects; costs associated with product warranties; Ouster's future capital needs and ability to secure additional capital on favorable terms or at all; inaccurate forecasts of market growth; Ouster's ability to manage growth; Ouster's ability to grow its sales and marketing organization; risks related to international operations, including international manufacturing; cancellation or postponement of contracts or unsuccessful implementations; Ouster's ability to maintain inventory and the risk of inventory write-downs; its ability to use tax attributes; Ouster's dependence on key third-party suppliers, in particular Benchmark Electronics, Inc. ("Benchmark"), Fabrinet and other suppliers; and its supply chain constraints and challenges; adverse conditions in the industries Ouster targets or the global economy more generally; Ouster's ability to recruit and retain key personnel; risks related to acquisitions, including integration risks and the failure to achieve anticipated benefits; risks related to the use of AI tools by us and others; Ouster's ability to effectively respond to evolving regulations and standards; Ouster's ability to adequately protect and enforce its intellectual property rights, including as it relates to Hesai; the impact of political events, trade and other international disputes and geopolitical tensions and other business interruptions on Ouster's business; changes to trade policy, tariffs, and import/export regulations; risks related to operating as a public company; and other important factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, that are further updated from time to time in the Company's other filings with the Securities and Exchange Commission (the "SEC"), including this Quarterly Report, that may cause its actual results, performance or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements.* 

*Any forward-looking statements made herein speak only as of the date of this Quarterly Report, and you should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, performance, or achievements reflected in the forward-looking statements will be achieved or occur. Except as required by applicable law, we undertake no obligation to update any of these forward-looking statements for any reason after the date of this Quarterly Report or to conform these statements to actual results or revised expectations.*

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**GENERAL**

Unless the context otherwise requires, references in this Quarterly Report to the terms "Ouster," "the Company," "we," "our" and "us" refer to the business and operations of Ouster, Inc.

We may announce material business and financial information to our investors using our investor relations website at https://investors.ouster.com. We therefore encourage investors and others interested in Ouster to review the information that we make available on our website, in addition to following our filings with the SEC, webcasts, press releases and conference calls. Information contained on our website is not part of this Quarterly Report.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**OUSTER, INC.** 

**CONDENSED CONSOLIDATED BALANCE SHEETS** 

**(unaudited)**

**(in thousands, except share and per share data)** 

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $78720 | $67413 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash, current | 647 | 1467 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 94398 | 141172 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 26195 | 27753 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 29878 | 23566 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 21169 | 17517 |
| Total current assets | 251007 | 278888 |
| Property and equipment, net | 33826 | 31891 |
| Operating lease, right-of-use assets | 13865 | 13452 |
| Unbilled receivable, non-current portion | 5240 | 8560 |
| Goodwill | 38525 |  |
| Intangible assets, net | 35007 | 13316 |
| Restricted cash, non-current | 1100 | 1100 |
| Other non-current assets | 2942 | 2309 |
| Total assets | $381512 | $349516 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $17403 | $19984 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued and other current liabilities | 38193 | 26200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities, current | 24159 | 20705 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability, current portion | 4561 | 4142 |
| Total current liabilities | 84316 | 71031 |
| Operating lease liability, non-current portion | 12824 | 12938 |
| Contract liabilities, non-current portion | 2951 | 3106 |
| Deferred tax liability | 5147 |  |
| Other non-current liabilities | 653 | 703 |
| Total liabilities | 105891 | 87778 |
| Commitments and contingencies (Note 7**)** |  |  |
| Stockholders' equity: |  |  |
| Common stock, $0.0001 par value; 100,000,000 shares authorized at March 31, 2026 and December 31, 2025; 63,461,091 and 60,947,757 issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 48 | 48 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1267048 | 1235580 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (990913) | (973448) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive (loss) income | (562) | (442) |
| Total stockholders' equity | 275621 | 261738 |
| Total liabilities and stockholders' equity | $381512 | $349516 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements

Note: Amounts as of December 31, 2025 are derived from the December 31, 2025 audited consolidated financial statements.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**OUSTER, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(unaudited)** 

**(in thousands, except share and per share data)** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product revenue | $48231 | $31105 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties | 347 | 1527 |
| Total revenue | 48578 | 32632 |
| Cost of revenue | 27740 | 19149 |
| Gross profit | 20838 | 13483 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 16082 | 14985 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 7840 | 6423 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 16128 | 15905 |
| Total operating expenses | 40050 | 37313 |
| Loss from operations | (19212) | (23830) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 2474 | 1705 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | (175) | 303 |
| Total other income, net | 2299 | 2008 |
| Loss before income taxes | (16913) | (21822) |
| Provision for income tax expense | 552 | 195 |
| Net loss | $(17465) | $(22017) |
| Other comprehensive income (loss) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in unrealized gain (loss) on available for sale securities | (120) | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments |  | 80 |
| Total comprehensive loss | $(17585) | $(21891) |
| Net loss per common share, basic and diluted | $(0.28) | $(0.42) |
| Weighted-average shares used to compute basic and diluted net loss per share | 61824843 | 52488199 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**OUSTER, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(unaudited)**

**(in thousands, except share data)** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-in-<br>Capital** | **Accumulated<br>Deficit** | **Accumulated other comprehensive income (loss)** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional<br>Paid-in-<br>Capital** | **Accumulated<br>Deficit** | **Accumulated other comprehensive income (loss)** | **Total<br>Stockholders'<br>Equity** |
| Balance — December 31, 2025 | 60947757 | $48 | $1235580 | $(973448) | $(442) | $261738 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock upon exercise of stock options | 44548 |  | 94 |  |  | 94 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock in connection with Stereolabs acquisition | 1847677 |  | 22779 |  |  | 22779 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock upon vesting of restricted stock units | 621109 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common stock warrants issuable to customer |  |  | 1101 |  |  | 1101 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense |  |  | 7494 |  |  | 7494 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  | (17465) |  | (17465) |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss |  |  |  |  | (120) | (120) |
| Balance — March 31, 2026 | 63461091 | $48 | $1267048 | $(990913) | $(562) | $275621 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-in-<br>Capital** | **Accumulated<br>Deficit** | **Accumulated other comprehensive income (loss)** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional<br>Paid-in-<br>Capital** | **Accumulated<br>Deficit** | **Accumulated other comprehensive income (loss)** | **Total<br>Stockholders'<br>Equity** |
| Balance — December 31, 2024 | 52560770 | $47 | $1094938 | $(913071) | $(1003) | 180911 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock upon exercise of stock options | 13558 |  | 28 |  |  | 28 |
| &nbsp;&nbsp;&nbsp;Issuance of common stock in connection with Velodyne Merger | 164394 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Issuance of common stock upon vesting of restricted stock units | 1118320 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Forfeited restricted stock awards | (68072) |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common stock warrants issuable to customer |  |  | 397 |  |  | 397 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense |  |  | 8498 |  |  | 8498 |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  | (22017) |  | (22017) |
| &nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  |  | 126 | 126 |
| Balance — March 31, 2025 | 53788970 | $47 | $1103861 | $(935088) | $(877) | $167943 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**OUSTER, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited)** 

**(in thousands)** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(17465) | $(22017) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 2703 | 1795 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on write-off and disposal of property and equipment |  | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on lease termination |  | (65) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 7494 | 8498 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | (360) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction of revenue related to stock warrant issued to customer | 1101 | 397 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use asset | 820 | 1245 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion on short-term investments | (454) | (822) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant liabilities |  | (112) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Recovery) provision for inventory write-down | (488) | 261 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recovery of doubtful accounts |  | (16) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realized gain on sale of available for sale securities | (9) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, net of effects of business acquisition: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 6472 | 4137 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (3665) | 1051 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (153) | (3883) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (3536) | 4120 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued and other liabilities | 134 | 8691 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities | 1020 | (6515) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability | (895) | (1660) |
| Net cash used in operating activities | (7281) | (4879) |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (2561) | (552) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of short-term investments | (10802) | (13858) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales and maturities of short-term investments | 57919 | 27000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition of Stereolabs, net of cash acquired | (27493) |  |
| Net cash provided by investing activities | 17063 | 12590 |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | 94 | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments received to fund employees tax obligation for vested RSUs | 611 | 632 |
| Net cash provided by financing activities | 705 | 660 |
| Effect of exchange rates on cash and cash equivalents |  | 80 |
| Net increase in cash, cash equivalents and restricted cash | 10487 | 8451 |
| Cash, cash equivalents and restricted cash at beginning of period | 69980 | 48099 |
| Cash, cash equivalents and restricted cash at end of period | $80467 | $56550 |
| **SUPPLEMENTAL DISCLOSURES OF OPERATING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax refunds, net of payments | $(2118) | $56 |
| **SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment purchases included in accounts payable and accrued liabilities | $333 | $129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets obtained in exchange for operating lease liability | $— | $440 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock shares issued in the acquisition of Stereolabs | $22780 | $— |

---

The accompanying notes are an integral part of these condensed consolidated financial statements

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**OUSTER, INC.** 

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** 

**(unaudited)**

**Note 1 – Description of Business and Basis of Presentation** 

***Description of Business***

Ouster, Inc. ("Ouster" or the "Company") was incorporated in the Cayman Islands on June 4, 2020 as "Colonnade Acquisition Corp." Following the closing of a business combination between the Company and Ouster Technologies, Inc. (formerly, Ouster, Inc.) in March 2021, the Company domesticated as a Delaware corporation and changed its name to "Ouster, Inc." Ouster is a leader in sensing and perception for Physical Artificial Intelligence (Physical AI). Ouster's product offerings enable machines to "Sense, Think, Act, and Learn" and independently execute tasks without human intervention. Physical AI allows machines to move beyond fixed, preprogrammed behavior into adaptive, intelligent action by focusing on perception, understanding, and learning from the physical world. Ouster offers a unified sensing and perception platform that combines high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and cutting-edge AI models to our customers.

On February 4, 2026 ("Closing Date"), the Company completed the acquisition of Stereolabs SAS ("Stereolabs"), accounted for as a business combination. See Note 3.

***Basis of Presentation and Principles of Consolidation***

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries (all of which are wholly owned) and have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") applicable to interim periods. All intercompany balances and transactions have been eliminated in consolidation. The presentation of certain prior period amounts has been reclassified to conform with current period presentation.

The unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of the results of operations for the periods shown. The unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2025 and the notes related thereto, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2026. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by applicable rules and regulations. The results of operations for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any other future years or interim periods.

***Liquidity***

The Company's principal sources of liquidity are its cash and cash equivalents, short-term investments, cash generated from sales of the Company's products, sales of common stock under its at-the-market equity offering program and debt financing.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis. The Company has experienced recurring losses from operations, and negative cash flows from operations. As of March 31, 2026, the Company's existing sources of liquidity included cash, cash equivalents, restricted cash and short-term investments of $174.9 million. The Company has incurred losses and negative cash flows from operations since inception. If the Company continues to incur losses in the future, it may need to improve liquidity and raise additional capital through the issuance of equity and/or debt. There can be no assurance that the Company would be able to raise such capital. However, management believes that the Company's existing sources of liquidity are adequate to fund its operations for at least twelve months from the date the unaudited condensed consolidated financial statements were available for issuance.

**Note 2 – Summary of Significant Accounting Policies**

During the three months ended March 31, 2026, except as noted below there were no significant changes to the Company's significant accounting policies as disclosed in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2026. The Company has consistently applied the accounting policies to all periods presented in these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Foreign Currencies***

The Company reassessed the functional currency of its foreign subsidiaries and determined it was the U.S. Dollar for all its subsidiaries. The impact of this change was not material. Foreign currency transaction gains and losses are recorded in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.

***Derivative Instruments and Hedging Arrangements Foreign Exchange Exposure Management***

The Company's wholly owned subsidiary, Stereolabs enters into forward foreign currency contracts to mitigate currency risk primarily related to forecasted Euro-denominated operating expenditures and assets and liabilities denominated primarily in the Euro. These foreign currency exchange contracts are entered into to support transactions made in the normal course of business, and accordingly, are not speculative in nature. The contracts are for periods consistent with the terms of the underlying transactions, generally one year or less. The fair value of our foreign currency forward contracts is determined using observable market inputs and is classified within Level 2 of the fair value hierarchy as defined by ASC 820, Fair Value Measurement. Changes in the fair value of these undesignated hedges are recognized in other income (expense), net immediately as an offset to the changes in the fair value of the asset or liability being hedged.

***Recently Issued and Adopted Accounting Pronouncements***

In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets ("ASU 2025-05"). This standard introduces a practical expedient that companies can choose to apply when determining allowances for credit losses. Specifically, it permits companies to assume that the current conditions as of the balance sheet date remain unchanged throughout the remaining life of the assets. Effective January 1, 2026, the Company adopted the amendments in this update for the annual period beginning fiscal year 2026 and applied the new requirements prospectively to the current annual period. The implementation of ASU 2025-05 did not have a material impact on the condensed consolidated financial statements.

***Recently Issued Accounting Pronouncements Not Yet Adopted***

The Company considers the applicability and impact of all ASUs. ASUs not referenced below were assessed and determined to be not applicable and are not expected to have a material impact on the Company's consolidated financial statements.

In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810) ("ASU 2025-03"), which clarifies the requirements for determining the accounting acquirer in the acquisition of a variable interest entity. ASU 2025-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. The amendments in this update require that an entity apply the new guidance prospectively to any acquisition transaction that occurs after the initial application date. Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the disclosure impact that ASU 2025-03 may have on its financial statement presentation and disclosures.

In May 2025, the FASB issued ASU 2025-04, Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) ("ASU 2025-04"), which clarifies the requirements for share-based consideration payable to a customer. The amendments in this update are effective for all entities for annual reporting periods (including interim reporting periods within annual reporting periods) beginning after December 15, 2026. Early adoption is permitted for all entities. The Company is currently evaluating the disclosure impact that ASU 2025-04 may have on its financial statement presentation and disclosures.

In November 2024, the FASB issued ASU 2024-03, "Disaggregation of Income Statement Expenses." The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures. The guidance is effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The guidance is to be applied prospectively, with the option for retrospective application. The Company is currently evaluating the impact of the ASU on the disclosures within the consolidated financial statements.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Concentrations of Credit Risk***

Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, short-term investments, accounts receivable and foreign currency forward exchange contracts. Although the Company deposits its cash, cash equivalents, restricted cash and short-term investments with financial institutions that Company believes are of high credit quality, its deposits, at times, may exceed federally insured limits. As of March 31, 2026 and December 31, 2025, the Company had cash, cash equivalents, short-term investments and restricted cash with financial institutions in the U.S. of $159.1 million and $201.3 million, respectively. As of March 31, 2026 and December 31, 2025, the Company also had cash with financial institutions in countries other than the U.S. of approximately $15.8 million and $9.9 million, respectively, that was not federally insured.

The Company generally does not require collateral or other security deposits for accounts receivable.

To reduce credit risk, the Company considers customer creditworthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms when determining the collectability of specific customer accounts. Past due balances over 90 days and other higher risk amounts are reviewed individually for collectability. Based on management's assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.

Accounts receivable from the Company's major customers representing 10% or more of total accounts receivable and unbilled receivable was as follows:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Customer A | 25% | 42% |
| Customer E | 30% | \* |
| Customer B | \* | 14% |
| Customer D | \* | 13% |

---

\*Customer accounted for less than 10% of total accounts receivable in the period.

Revenue from the Company's major customers representing 10% or more of total revenue was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Customer E | 31% | 15% |
| Customer F | —% | 19% |
| Customer H | 11% | \* |

---

\*Customer accounted for less than 10% of total revenue in the period.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Concentrations of Supplier Risk***

Purchases from the Company's suppliers and vendors representing 10% or more of total purchases were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Supplier A | \* | 11% |
| Supplier B | 30% | 27% |

---

\*Supplier accounted for less than 10% of total purchases in the period.

Accounts payable to the Company's major suppliers and professional services vendors representing 10% or more of total accounts payable were as follows:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Supplier A | \* | 13% |
| Supplier B | 60% | 50% |
| Supplier C | \* | 10% |

---

\*Accounted for less than 10% of total accounts payable.

**Note 3. Business Combination and Related Transactions**

On the Closing Date, the Company acquired 100% of the outstanding share capital of Stereolabs, a privately-held developer, manufacturer and seller of vision systems headquartered in France. The acquisition expanded the Company's product portfolio, and is expected to further strengthen its software capabilities and accelerated customer development.

Shareholders of Stereolabs received cash consideration of $32.4 million and 1,847,677 newly issued shares of the Company's common stock, of which 660,005 shares are subject to a staggered lock-up arrangement lasting through a four-year period, whereby twenty-five (25%) percent will be released upon each anniversary of the completion date contingent upon employees remaining employed by the Company. See Note 9.

The consideration paid was comprised of cash and common stock, as follows (in thousands):

---

| | |
|:---|:---|
| Consideration: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash consideration | $32392 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value of common stock issued, less shares subject to continued employment requirements<sup>(1)</sup> | 22780 |
|  | $55172 |

---

<sup>(1)</sup> Calculated based upon 1,187,672 shares at the stock price of $19.18 per share on the Closing Date.

The Company accounted for the acquisition of Stereolabs as a business combination under ASC 805. This accounting treatment requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. In accordance with ASC 805, the total purchase price was allocated to identifiable tangible and intangible assets acquired and liabilities assumed based on their respective estimated fair values using management's best estimates and assumptions to assign fair value as of the acquisition date. The allocation of the purchase price to the assets acquired and liabilities assumed is subject to further adjustment within the measurement period which extends up to one year from the acquisition date.

The Company incurred $5.0 million in acquisition costs for Stereolabs, of which $3.9 million was incurred in the year ended December 31, 2025, and $1.2 million was incurred in three months ended March 31, 2026. These costs were expensed as incurred. Acquisition-related costs are presented within general and administrative expenses in the Company's condensed consolidated statement of operations. In addition, the sellers incurred transaction costs of $3.0 million which were paid by the Company on the Closing Date.

The following table provides the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

---

| | |
|:---|:---|
| | **Estimated Fair Value** |
| Purchase consideration | $55172 |
| Amounts of identifiable assets and liabilities assumed |  |
| &nbsp;&nbsp;Cash and cash equivalents | $4899 |
| &nbsp;&nbsp;Accounts receivable, net | 1594 |
| &nbsp;&nbsp;Inventory | 2159 |
| &nbsp;&nbsp;Prepaid expenses and other current assets <sup>(1)</sup> | 4065 |
| &nbsp;&nbsp;Property and equipment, net | 701 |
| &nbsp;&nbsp;Operating lease, right-of-use assets | 1233 |
| &nbsp;&nbsp;Intangible assets, net | 23400 |
| &nbsp;&nbsp;Other non-current assets | 66 |
| &nbsp;&nbsp;Accounts payable | (1692) |
| &nbsp;&nbsp;Accrued and other current liabilities | (10792) |
| &nbsp;&nbsp;Contract liabilities, current | (2279) |
| &nbsp;&nbsp;Operating lease liability, current portion | (197) |
| &nbsp;&nbsp;Operating lease liability, non-current portion | (1003) |
| &nbsp;&nbsp;Deferred tax liability | (5507) |
| Total identifiable net assets | $16647 |
| Goodwill | 38525 |
|  | $55172 |

---

<sup>(1)</sup> Prepaid expenses and other current assets includes a $1.9 million indemnification asset, with the underlying indemnified liability of $6.3 million recorded within accrued and other current liabilities.

Identified intangible assets acquired and their estimated useful lives as of February 4, 2026, were (in thousands, except years):

---

| | | |
|:---|:---|:---|
| | **Estimated Useful Life<br>(in years)** | **Estimated Fair Value** |
| Trade name | 6 | $1500 |
| Developed technology | 4 | 14000 |
| Customer relationships | 8 | 7900 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net |  | $23400 |

---

Developed technology relates to Stereolabs' vision-based perception and Artificial Intelligence ("AI") platform that provides real-time depth sensing, 3D mapping, and object detection in complex real-world environments. The Company valued the developed technology using the relief-from-royalty method under the income approach, which involved assumptions related to the economic life, obsolescence curve, and discount rate. The economic life was determined based on the development cycle, benchmarking analysis, and the projected cash flows over the forecasted period.

The estimated fair value of the trade name was determined using the relief-from-royalty method under the income approach, which involved assumptions related to the economic life and discount rate. The Stereolabs trade name is expected to be in use for the foreseeable future and the economic life was determined based on the branding strategy, benchmarking analysis, and the projected cash flows over the forecasted period.

The Company valued the customer relationship intangible asset using the multi-period excess earnings method under the income approach, which involved assumptions related to the economic life and discount rate. The economic life was determined based on expected attrition and existing customer revenue growth, as well the period over which the majority of discounted cash flows would be realized.

The excess of the purchase consideration and the fair value of identifiable assets acquired and liabilities assumed at the acquisition date over the fair value of net tangible and identified intangible assets acquired was recorded as goodwill, which is deductible for tax purposes. Goodwill is primarily attributable to the assembled workforce and the anticipated operational synergies expected from the Stereolabs acquisition.

Approximately $1.9 million of the cash consideration is held in an escrow account to cover estimated claims arising from pre-closing tax accruals related to certain historical foreign sales transactions and other taxes ("the Specific Tax Loss"). Any

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

remaining portion of the escrow amount that is not required to cover the Specific Tax Loss amounts will be paid to the former shareholders of Stereolabs at December 31, 2027 (the escrow release date). The indemnification of the Specific Tax Loss is capped at $1.9 million, the amount of the escrow fund balance. At the acquisition date, the associated Specific Tax Loss was recorded at the estimated fair value of $6.3 million within accrued and other current liabilities and the Company recorded an indemnification asset up to the amount of the escrow fund balance of $1.9 million.

The unaudited supplemental pro forma information below presents the combined historical results of operations of the Company and Stereolabs as if Stereolabs had been acquired as of January 1, 2025 (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue | $50216 | $34371 |
| Net loss | $(24245) | $(31848) |

---

The unaudited supplemental pro forma information above includes the following adjustments to net loss in the appropriate pro forma periods (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| An increase in amortization expense related to the fair value of acquired identifiable intangible assets, net of the amortization expense already reflected in actual historical results. | $(484) | $(1184) |
| A decrease (increase) in expenses related to the transaction expenses. This amount includes $3.0 million in transaction expenses incurred by the sellers. | $4137 | $(8022) |
| An increase in additional stock-based compensation expense related to shares issued to key Stereolabs employees in the acquisition that are considered compensatory in the post business combination periods due to the additional service requirement, net of the stock compensation expense already reflected in actual historical results. | $(303) | $(780) |
| A decrease (increase) in additional stock-based compensation expense related to the impact of the acceleration of Stereolabs warrants that vested at the close of the Stereolabs acquisition.  | $207 | $(207) |

---

The unaudited supplemental pro forma information has been presented for illustrative purposes only and is not necessarily indicative of results of operations that would have been achieved had the Stereolabs taken place on the date indicated, or of the Company's future consolidated results of operations. The supplemental pro forma information presented above has been derived from the Company's historical consolidated financial statements and from historical consolidated financial statements and the historical accounting records of Stereolabs.

**Note 4. Fair Value of Financial Instruments** 

The following tables provides information by level for the Company's assets that were measured at fair value on a recurring basis (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Level 1** | **Level 2** | **Total** |
| Assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $60427 | $— | $60427 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 30420 | 30420 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities |  | 63978 | 63978 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total short-term investments |  | 94398 | 94398 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total financial assets | $60427 | $94398 | $154825 |

---

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Level 1** | **Level 2** | **Total** |
| Assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $54475 | $— | $54475 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 68326 | 68326 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate debt securities |  | 72846 | 72846 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total short-term investments |  | 141172 | 141172 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total financial assets | $54475 | $141172 | $195647 |

---

Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.

The value of securities included in Level 2 are based on other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

The value and changes in Level 3 liabilities measured at fair value on a recurring basis are immaterial.

*Non-Recurring Fair Value Measurements*

The Company has certain assets, including intangible assets, which are measured at fair value on a non-recurring basis and are adjusted to fair value only if an impairment charge is recognized. The categorization of the framework used to measure fair value of the assets is considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used.

*Disclosure of Fair Values* 

The Company's financial instruments that are not re-measured at fair value include accounts receivable, accounts payable, accrued and other current liabilities. The carrying values of these financial instruments approximate their fair values. Unrealized gains and losses on the Company's short-term investments were not significant as of March 31, 2026 and December 31, 2025, and therefore, the amortized cost of the Company's short-term investments approximated its fair value.

*Derivatives*

Stereolabs uses foreign currency forward exchange contracts to mitigate currency risk primarily related to forecasted Euro-denominated operating expenditures and assets and liabilities denominated primarily in the Euro. These derivatives are carried at fair value with changes recorded in interest income and other, net in the condensed consolidated statements of operations. Changes in the fair value of these derivatives are largely offset by re-measurement of the underlying assets and liabilities. Cash flows from such derivatives are classified as operating activities. The derivatives have maturities from approximately 0.2 to 0.8 years.

The following table summarizes the Company's outstanding derivative instruments on a gross basis as recorded in its condensed consolidated balance sheets as of March 31, 2026 (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **At March 31, 2026** | **At March 31, 2026** | **At March 31, 2026** |
| | **Notional Amount** | **Balance Sheet Line Item** | **Derivative Liabilities Fair Value** |
| Undesignated hedges: Forward foreign currency exchange contracts | $4500 | (a) | $99 |

---

(a) Other current liabilities

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Note 5. Balance Sheet Components** 

***Cash and Cash Equivalents***

The Company's cash and cash equivalents consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Cash | $18293 | $12938 |
| Cash equivalents: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money market funds<sup>(1)</sup> | 60427 | 54475 |
| Total cash and cash equivalents | $78720 | $67413 |

---

<sup>(1)</sup> The Company maintains a cash sweep account, which is included in money market funds as of March 31, 2026 and December 31, 2025. Cash is invested in short-term money market funds that earn interest.

***Restricted Cash***

Restricted cash consists of collateral to merchant credit card, deposit account to secure foreign entity closure costs, issuances of deposit performance guarantee issued in favor of a customer, and certificates of deposit held by a bank as security for outstanding letters of credit. The Company had a restricted cash balance of $1.7 million and $2.6 million as of March 31, 2026 and December 31, 2025, respectively, which has been excluded from the Company's cash and cash equivalents balances. The Company presented $0.6 million and $1.5 million of the total amount of restricted cash within current assets on the unaudited condensed consolidated balance sheets as of March 31, 2026 and December 31, 2025, respectively. The remaining restricted cash balance of $1.1 million and $1.1 million is included in non-current assets on the condensed consolidated balance sheets as of March 31, 2026 and December 31, 2025, respectively.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the unaudited condensed consolidated balance sheets to the total of the amounts reported in the unaudited condensed consolidated statements of cash flows (in thousands):

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **March 31,<br>2025** |
| Cash and cash equivalents | $78720 | $53984 |
| Restricted cash, current | 647 | 731 |
| Restricted cash, non-current | 1100 | 1835 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash, cash equivalents and restricted cash | $80467 | $56550 |

---

***Inventory***

Inventory, consisting of material, direct and indirect labor, and manufacturing overhead, consists of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Raw materials | $9041 | $3866 |
| Work in process | 1565 | 93 |
| Finished goods | 19272 | 19607 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total inventory | $29878 | $23566 |

---

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Prepaid expenses and other current assets***

Prepaid expenses and other current assets consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Prepaid expenses | $5750 | $3529 |
| Prepaid inventory | 3098 | 2887 |
| Prepaid insurance | 1745 | 967 |
| Receivable from contract manufacturer | 3926 | 3497 |
| IRS Income tax refund receivable |  | 2993 |
| Indemnification asset (See Note 3.) | 1855 |  |
| Other current assets | 4795 | 3644 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total prepaid expenses and other current assets | $21169 | $17517 |

---

***Property and Equipment, net***

Property and equipment consists of the following (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **Estimated Useful Life<br>(in years)** | **March 31,<br>2026** | **December 31,<br>2025** |
| Land | Not depreciated | $7798 | $7798 |
| Building | 25 | 9453 | 9453 |
| Machinery and equipment | 3 | 17851 | 16640 |
| Computer equipment | 3 | 1373 | 1140 |
| Automotive and vehicle hardware | 5 | 93 | 93 |
| Software | 3 | 438 | 160 |
| Furniture and fixtures | 7 | 1129 | 863 |
| Construction in progress |  | 8231 | 7326 |
| Leasehold improvements | Shorter of useful life or lease term | 5134 | 5097 |
|  |  | 51500 | 48570 |
| Less: Accumulated depreciation |  | (17674) | (16679) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net |  | $33826 | $31891 |

---

Depreciation expense associated with property and equipment was $1.0 million and $0.7 million during the three months ended March 31, 2026 and 2025, respectively.

***Goodwill and Acquired Intangible Assets, Net***

The changes in the carrying amount of goodwill are as follows (in thousands):

---

| | |
|:---|:---|
| | **Amount** |
| &nbsp;&nbsp;Balance at December 31, 2025 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill addition related to Stereolabs acquisition | 38525 |
| &nbsp;&nbsp;Balance at March 31, 2026 | $38525 |

---

Annually, and/or upon the identification of a triggering event, management is required to perform an assessment of fair value relative to carrying value of goodwill. Triggering events potentially warranting an interim goodwill impairment test include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained declines in the Company's stock price or market capitalization, considered both in absolute terms and relative to peers.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

The following tables present acquired intangible assets, net as of March 31, 2026 and December 31, 2025 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Estimated Useful Life<br>(in years)** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** |
| Trade name | 6 | $1500 | $(37) | $1463 |
| Developed technology | 3-8 | 37500 | (14994) | 22506 |
| Vendor relationship | 3 | 6600 | (6600) |  |
| Customer relationships | 3 - 8 | 14200 | (3162) | 11038 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net |  | $59800 | $(24793) | $35007 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Estimated Useful Life<br>(in years)** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** |
| Developed technology | 3-8  | $23500 | $(13634) | $9866 |
| Vendor relationship | 3 | 6600 | (6600) |  |
| Customer relationships | 3-8 | 6300 | (2850) | 3450 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net |  | $36400 | $(23084) | $13316 |

---

Amortization expense was $1.7 million and $1.1 million during the three months ended March 31, 2026 and 2025, respectively.

The following table summarizes estimated future amortization expense of finite-lived intangible assets-net (in thousands):

---

| | |
|:---|:---|
| Years: | **Amount** |
| &nbsp;&nbsp;Remainder of 2026 | $6333 |
| &nbsp;&nbsp;2027 | 8416 |
| &nbsp;&nbsp;2028 | 7526 |
| &nbsp;&nbsp;2029 | 7065 |
| &nbsp;&nbsp;2030 | 2257 |
| &nbsp;&nbsp;Thereafter | 3410 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $35007 |

---

***Accrued and Other Current Liabilities***

Accrued and other current liabilities consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Accrued legal fees and contingencies | $2801 | $2124 |
| Uninvoiced receipts | 10900 | 7910 |
| Accrued compensation | 8012 | 7415 |
| Warranty reserve | 2137 | 1800 |
| Sales, use, value-added taxes, customs duties and other taxes<sup>(1)</sup> | 9835 | 3108 |
| Other | 4508 | 3843 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total accrued and other current liabilities | $38193 | $26200 |

---

<sup>(1)</sup> Includes indemnified Specific Tax Loss Liabilities of $6.3 million from the Stereolabs acquisition. The indemnification of the Specific Tax Loss is capped at $1.9 million. See Note 3.

**Note 6. Amazon Warrant**

On February 10, 2023, as part of the Velodyne Merger, the Company assumed a warrant agreement and a transaction agreement, pursuant to which Velodyne agreed to issue to Amazon.com NV Investment Holdings LLC, a wholly-owned subsidiary of Amazon.com Inc. ("Amazon"), a warrant to acquire, following customary antidilution adjustments, up to an aggregate of 3,263,898 shares of the Company's common stock at an exercise price of $50.71 per share (the "Amazon Warrant"). The exercise price and the warrant shares issuable upon exercise of the Amazon Warrant are subject to further

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

antidilution adjustments, including in the event the Company makes certain sales of common stock (or securities exercisable or convertible into or exchangeable for shares of the Company's common stock) at a price less than the exercise price of the Amazon Warrant. During the three months ended March 31, 2026, the Company issued an additional 1,847,677 shares of common stock pursuant to the Stereolabs acquisition at effective prices below the exercise price of the Amazon Warrant, resulting in an antidilution adjustment to the terms of the Amazon Warrant with an increase in the number of shares issuable under the Amazon Warrant by 5,185 shares of common stock and a reduction to the original strike price of the Amazon Warrant to $50.49 per share. As of March 31, 2026, there were 3,277,155 shares of common stock issuable under the Amazon Warrant.

The Amazon Warrant shares vest in multiple tranches over time based on payments of up to $100.0 million by Amazon or its affiliates (directly or indirectly through third parties) to the Company in connection with Amazon's purchase of goods and services. The fair value of the unvested Amazon Warrant will be recognized as a non-cash stock-based reduction to revenue when Amazon makes payments and vesting conditions become probable of being achieved.

The fair value of the Amazon Warrant shares was estimated on February 10, 2023, the date of completion of the Velodyne Merger, using the Black-Scholes option pricing model on the remaining contractual term of 6.98 years, an expected volatility of 53.7%, a 3.86% risk-free interest rate and a 0% expected dividend yield.

The right to exercise the Amazon Warrant and receive the warrant shares that have vested expires February 4, 2030.

In the three months ended March 31, 2026, 142,890 Amazon Warrant shares vested. As of March 31, 2026, there were 2,871,875 Amazon Warrant shares vested.

**Note 7. Commitments and Contingencies**

***Letters of Credit***

In connection with certain office leasehold interests in real property located in San Francisco (350 Treat Ave. and 2741 16th Street), the Company obtained letters of credit from certain banks as required by the lease agreements. If the Company defaults under the terms of the applicable lease, the lessor will be entitled to draw upon the letters of credit in the amount necessary to cure the default. The amounts covered by the letters of credit are collateralized by certificates of deposit, which are included in restricted cash on the condensed consolidated balance sheets as of March 31, 2026 and December 31, 2025. The amount collateralizing the 2741 16th Street lease letter of credit following the purchase of the property and the termination of the 2741 16th Street lease was released during the first fiscal quarter of 2026. The outstanding amount of the letters of credit was $0.3 million and $1.4 million as of March 31, 2026 and December 31, 2025, respectively.

***Non-cancelable purchase commitments***

As of March 31, 2026, the Company had non-cancelable purchase commitments to third-party contract manufacturers for approximately $13.0 million and other vendors for approximately $26.3 million.

***Contingencies***

From time to time, the Company may be involved in legal and administrative proceedings arising in the ordinary course of business. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. Management reviews these estimates in each accounting period as additional information becomes known and adjusts the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements. If a loss is probable but the amount of loss cannot be reasonably estimated, the Company discloses the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made). Legal costs incurred in connection with loss contingencies are expensed as incurred.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Litigation***

The Company is involved in various legal proceedings arising in the ordinary course of business. Significant judgment is required in both the determination of probability and the determination as to whether any exposure is reasonably estimable. Actual outcomes of these legal and regulatory proceedings may materially differ from our current estimates.

*Velodyne Legacy Litigation*

In 2022, David and Marta Hall filed a lawsuit against current and former officers and directors of Velodyne, which proceeded through arbitration. In addition, in 2023, David and Marta Hall filed a separate complaint against Velodyne seeking indemnification for legal fees. The parties agreed to a confidential settlement, without any admission or concession of wrongdoing or liability, for both matters and executed the definitive agreement on April 16, 2025. As of December 31, 2024, the Company accrued the settlement expenses associated with these actions, and paid an immaterial amount in settlement expenses in the second quarter of fiscal 2025. An insurance receivable allowed the Company to recover the majority of the settlement expenses, resulting in a net charge that was immaterial to its consolidated statement of operations

In 2023, a putative shareholder class action suit was filed in Delaware against former officers and directors of Graf Acquisition LLC (Velodyne was not named as a defendant). The parties agreed to a settlement without any admission or concession of wrongdoing or liability. As of June 30, 2025, the Company accrued the expected settlement expenses associated with this action. An insurance receivable allowed the Company to recover the majority of the expected settlement expenses, resulting in a net charge that was immaterial to its consolidated statement of operations. The court approved the settlement and entered final judgment on October 8, 2025.

*Ouster Litigation*

On April 11, 2023, the Company filed a complaint in the District of Delaware alleging patent infringement of certain claims of the Company's U.S. Patent Nos. 11,175,405, 11,178,381, 11,190,750, 11,287,515, and/or 11,422,236 against Hesai Group and Hesai Technology Co., Ltd. Subject to the terms of a confidential decision in the arbitration described below, the Company dismissed without prejudice this case on April 11, 2025.

On May 17, 2023, Hesai Photonics Technology Co. Ltd. and Hesai Group (collectively "Hesai Photonics") filed a request for arbitration with JAMS against the Company, Velodyne Lidar, Inc., Velodyne, LLC, and Oban Merger Sub II LLC. Hesai Photonics alleges that the Company is bound as a result of the Company's 2023 merger with Velodyne Lidar, Inc. by the terms and conditions, including an obligation to arbitrate disputes, of a long-term, global cross-licensing settlement agreement signed in 2020 between Hesai Photonics and Velodyne Lidar, Inc. ("Velodyne-Hesai Settlement Agreement"). On June 13, 2023, the Company responded to the arbitration demand and denied all allegations. On March 28, 2025, the tribunal issued a confidential interim decision, finding that the Company was subject to the Velodyne-Hesai Photonics Settlement Agreement. On September 15, 2025, the tribunal issued a confidential final decision, affirming the earlier finding of a global licensing settlement agreement that requires Hesai Photonics to pay royalties and deciding on fees in the amount of approximately $6.4 million, which the Company paid in the fourth quarter of fiscal 2025.

On September 14, September 25, and September 26, 2023, Hesai filed Petitions for Inter Partes Review with the Patent Trial and Appeal Board ("PTAB") challenging the validity of the Company's patents asserted in the ITC and Delaware patent actions. The Company provided preliminary responses to those petitions in late December 2023 and early January 2024. On March 19, 2024, March 28, 2024, and April 1, 2024, the PTAB issued decisions to institute inter partes review for four patents: IPR2023-01421 (Patent No. 11,175,405), hearing date of December 17, 2024; IPR2023-01422 (Patent No. 11,287,515), hearing date of December 17, 2024; IPR2023-01456 (Patent No. 11,178,381), hearing date of January 13, 2025; and IPR2023-01457 (Patent No. 11,190,750), hearing date of January 13, 2025. On March 13, 2025, the PTAB issued final written decisions upholding the patentability of all challenged claims in IPR2023-01422, and finding unpatentable all challenged claims in IPR2023-01421 and IPR2023-01457. On March 17, 2025, the PTAB issued a final written decision finding unpatentable all challenged claims of IPR2023-01456. On June 2 and 3, 2025, the Company filed notices of appeal for IPR2023-01421, IPR 2023-01426, and IPR 2023-01457, but the parties dismissed all but IPR2023-01421, which is awaiting hearing. Regarding the fifth patent (Patent No. 11,422,236), the PTAB declined to institute on March 28, 2024, (see IPR2023-01458). Hesai requested review to the Director of the United States Patent and Trademark Office ("Director Review"), who remanded to the PTAB for further review of its decision not to institute. On January 21, 2025, the PTAB again denied institution, to which Hesai again requested Director Review, and the Company objected. On March 20, 2025, the Director again denied review.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Indemnification***

From time to time, the Company enters into agreements in the ordinary course of business that include indemnification provisions. Generally, in these provisions the Company agrees to defend, indemnify, and hold harmless the indemnified parties for claims and losses suffered or incurred by such indemnified parties for which the Company is responsible under the applicable indemnification provisions. The terms of the indemnification provisions vary depending upon negotiations between the Company and its counterpart; however, typically, these indemnification obligations survive the term of the contract and the maximum potential amount of future payments the Company could be required to make pursuant to these provisions are uncapped.

The Company has also entered into indemnity agreements pursuant to which it has indemnified its directors and officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual may be involved by reason of such individual being or having been a director or executive officer, other than liabilities arising from willful misconduct of the individual. To date, the Company is indemnifying and has incurred costs to defend lawsuits or settle claims described above under the heading "Litigation" pursuant to the indemnity agreements of former directors and officers.

**Note 8. Common Stock**

Pursuant to the terms of the Second Amended and Restated Certificate of Incorporation, the Company is authorized to issue the following shares and classes of capital stock, each with a par value of $0.0001 per share: (i) 100,000,000 shares of common stock; (ii) 100,000,000 shares of preferred stock. The holder of each share of common stock is entitled to one vote.

On May 12, 2025, the Company entered into an At-Market-Issuance Sales Agreement (the "ATM Agreement") with Oppenheimer & Co. Inc., pursuant to which the Company may offer and sell, from time to time, through or to the agent, acting as agent or principal, shares of the Company's common stock, having an aggregate offering price of up to $100.0 million.

During the three months ended March 31, 2026, no shares of common stock were sold under the ATM Agreement. The remaining availability under the ATM Agreement as of March 31, 2026 is approximately $2.5 million.

On November 9, 2025, the Company agreed to issue shares of common stock for the acquisition of Stereolabs. See Note 3. Upon the closing of the Stereolabs transaction on February 4, 2026, the Company issued 1,847,677 shares, inclusive of 660,005 shares which will be released over a four-year period. The Company sold the foregoing securities in transactions not involving an underwriter and not requiring registration under Section 5 of the Securities Act of 1933, as amended (the "Securities Act") in reliance on the exemptions afforded by Section 4(a)(2) and/or Regulation S of the Securities Act and the rules and regulations promulgated thereunder.

**Note 9. Stock-based Compensation** 

As of March 31, 2026, the Company maintains five equity incentive plans: its Amended and Restated 2015 Stock Plan (the "2015 Plan"), the Sense Photonics, Inc. 2017 Equity Incentive Plan (the "Sense Plan"), the Velodyne Lidar, Inc. 2020 Equity Incentive Plan (the "Velodyne Plan"), its 2021 Incentive Award Plan (the "2021 Plan") and its Amended and Restated 2022 Employee Stock Purchase Plan (the "2022 ESPP" and, collectively with the 2015 Plan, the Sense Plan, the Velodyne Plan and the 2021 Plan, the "Plans").

The Plans, other than the 2022 ESPP, provide for the grant of stock options, stock appreciation rights, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), performance stock unit awards and other forms of equity compensation (collectively, "equity awards"). In addition, the 2021 Plan provides for the grant of performance bonus awards. New equity awards may only be granted under the 2021 Plan and Velodyne Plan. Awards under the 2021 Plan and Velodyne Plan can be granted to employees, including officers, directors and consultants of the Company and its subsidiaries, in each case, within the limits provided in the 2021 Plan and Velodyne Plan, respectively.

The Company's 2022 ESPP has been offered to all eligible employees since August 2022 and generally permits certain employees to purchase shares of our common stock at a discount through payroll deductions of up to 15% of their compensation during each offering period, subject to certain limitations.

The 2022 ESPP provides offering periods that have a duration of 24 months in length and are comprised of purchase periods of six months in length. The offering periods are scheduled to start on the first trading day on or after May 16 and November 16 of each year. Under the 2022 ESPP, the purchase price of a share equals 85% of the lesser of the fair market value of a share of common stock on either the first or last day of the applicable offering period or the last day of the applicable purchase period.

During the three months ended March 31, 2026, there were no shares of common stock issued under the 2022 ESPP.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

The stock-based compensation expense for the 2022 ESPP is based on the estimated grant date fair value utilizing the Black-Scholes option valuation model of the 2022 ESPP shares and the number of shares that can be purchased as of the grant date, which is recognized as expense on a straight line expense attribution method over the length of an offering period.

*Stock Options*

Stock option activity for the three months ended March 31, 2026 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of<br>Shares<br>Underlying<br>Outstanding<br>Options** | **Weighted-<br>Average Exercise<br>Price** | **Weighted-<br>Average<br>Remaining<br>Contractual<br>Term (in years)** | **Aggregate<br>Intrinsic<br>Value** |
| Outstanding—December 31, 2025 | 1710622 | $7.69 | 4.72 | $24142 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options exercised | (44548) | 2.10 |  |  |
| Outstanding—March 31, 2026 | 1666074 | $7.84 | 4.47 | $17854 |
| Vested —March 31, 2026 | 1666074 | $7.84 | 4.47 | $17854 |
| Exercisable—March 31, 2026 | 1666074 | $7.84 | 4.47 | $17854 |

---

The following table summarizes information about stock options outstanding and exercisable at March 31, 2026.

---

| | | | |
|:---|:---|:---|:---|
| | **Options Outstanding** | **Options Outstanding** | **Options<br>Exercisable** |
|<br>**Exercise<br>Price** | **Options<br>Outstanding** | **Weighted<br>Average<br>Remaining<br>Contractual<br>Life (Years)** | **Options<br>Exercisable** |
| $1.85 | 163315 | 4.29 | 163315 |
| 2.13 | 741142 | 4.50 | 741142 |
| 14.22 | 752408 | 4.50 | 752408 |
| 52.40 | 9209 | 3.50 | 9209 |
|  | 1666074 |  | 1666074 |

---

As of March 31, 2026, there was no remaining unamortized stock-based compensation expense related to unvested stock options.

*Restricted Stock Units*

A summary of RSU activity for the three months ended March 31, 2026 was as follows:

---

| | | |
|:---|:---|:---|
| | **Number of<br>Shares** | **Weighted Average<br>Grant Date Fair<br>Value (per share)** |
| Unvested—December 31, 2025 | 4085075 | $12.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted | 149677 | 24.96 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canceled | (56253) | 10.51 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | (621109) | 10.76 |
| Unvested—March 31, 2026 | 3557390 | $12.81 |

---

Stock-based compensation expense is recognized on a straight-line basis over the vesting period of each award of RSUs. As of March 31, 2026, total compensation expense related to unvested RSUs granted to employees, but not yet recognized, was $36.2 million, with a weighted-average remaining vesting period of 1.7 years. RSUs settle into shares of common stock upon vesting.

*Stereolabs acquisition*

In connection with the acquisition of Stereolabs (Note 3), several Stereolabs key employees entered into agreements with the Company whereby these key employees are eligible to receive an aggregate of 660,005 shares of common stock subject to their continued employment with the Company. These shares are excluded from the above restricted stock units table. These shares are considered compensatory in the post-business combination periods due to the additional service requirement for these key employees. These shares are subject to a staggered lock-up arrangement lasting through a four-year period, whereby twenty-five (25%) percent will be released upon each anniversary of the completion date as long as the key employees are still

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

employees of the Company. As of March 31, 2026, there were 660,005 unvested shares outstanding with a grant date fair value of $19.18 per share subject to future service periods. The Company recognized stock-based compensation expense of $0.5 million during the three months ended March 31, 2026 related to the 660,005 shares. As of March 31, 2026, there is $12.2 million remaining unamortized compensation expense that will be recognized over a weighted average remaining period of 3.9 years.

*Stock-Based Compensation Expense*

The Company recognized stock-based compensation expense for all share-based awards in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Cost of revenue | $826 | $1137 |
| Research and development | 2616 | 4305 |
| Sales and marketing | 766 | 1106 |
| General and administrative | 3286 | 1950 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation | $7494 | $8498 |

---

The following table summarizes stock-based compensation expense by award type (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| RSUs | $6449 | $7333 |
| Employee stock purchase plan | 361 | 340 |
| RSAs |  | 825 |
| Stereolabs post-combination compensation expense | 684 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation | $7494 | $8498 |

---

**Note 10. Net Loss Per Common Share** 

The following table sets forth the computation of basic and diluted net loss per common share attributable to common stockholders (in thousands, except share and per share data):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Numerator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(17465) | $(22017) |
| Denominator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average shares used to compute basic and diluted net loss per share | 61824843 | 52488199 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss per common share—basic and diluted | $(0.28) | $(0.42) |

---

The weighted average number of shares used to compute basic and diluted net loss per share excludes unvested early exercised common stock options subject to repurchase.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

---

| | | |
|:---|:---|:---|
| | **March 31,** | **March 31,** |
| | **2026** | **2025** |
| Options to purchase common stock | 1666074 | 1741440 |
| Public and private common stock warrants | 3277155 | 5235409 |
| Restricted Stock Units | 3557390 | 5426805 |
| Shares issued to Stereolabs employees and subject to vesting | 660005 |  |
| Share purchase rights under the ESPP | 267175 | 549260 |
| Unvested RSAs |  | 388626 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 9427799 | 13341540 |

---

**Note 11. Income Taxes** 

The Company's income tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items arising in the quarter. The tax provision for the three months ended March 31, 2026 was $0.6 million, which includes $0.9 million of discrete items primarily related to withholding taxes on sales to customers.

The Company's effective tax rate was (3.3)% for the three months ended March 31, 2026 and (0.9)% for the three months ended March 31, 2025. The Company's effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on the deferred tax assets as it is more likely than not that some, or all, of the Company's deferred tax assets will not be realized. The Company continues to maintain a full valuation allowance against its net deferred tax assets. Due to tax losses and the offsetting valuation allowance, the income tax provision for the three months ended March 31, 2025 was immaterial to the Company's unaudited condensed consolidated financial statements.

**Note 12. Revenue**

The majority of the Company's revenue is recognized at the point in time when the customer obtains control of the respective lidar sensors, cameras and AI compute systems. Revenue recognized over time is immaterial to total revenue recognized for any given period.

Revenue for the three months ended March 31, 2026 and 2025, respectively, includes patent royalty revenues generated from a long-term intellectual property ("IP") license agreement in the amount of $0.3 million and $1.5 million. The Company also expects to record future revenue from this agreement as it satisfies its performance obligations.

The following table presents total revenues by geographic area based on the location products were shipped to and services provided (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Americas | $32798 | $15528 |
| Asia and Pacific<sup>(1)</sup> | 7990 | 12464 |
| Europe, Middle East and Africa | 7790 | 4640 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $48578 | $32632 |

---

<sup>(1)</sup> In the three months ended March 31, 2026 and 2025, respectively, the Company recognized $0.3 million and $1.5 million of patent royalty revenue from a long-term IP license agreement.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

Countries that accounted for more than 10% of total revenue were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| United States | 66% | 45% |
| Austria | 11% | \* |
| Thailand | \* | 23% |

---

\*Country accounted for less than 10% of total revenue in the period.

***Revenue contract balances***

Timing of revenue recognition may differ from the timing of invoicing to customers. An unbilled receivable is recorded in instances when revenue is recognized prior to invoicing, and amounts collected in advance of services being provided are recorded as deferred revenue. Contract assets and liabilities are generated when contractual billing schedules differ from revenue recognition timing.

*Unbilled receivables*

A receivable for multi-year licensing services is generally recorded upon invoicing. A receivable for multi-year license agreements is recorded upon delivery, whether or not invoiced, to the extent the Company has an unconditional right to receive payment in the future related to those licenses. As of March 31, 2026, the current portion of these unbilled receivables in the amount of $3.4 million, primarily consisting of unbilled receivables from multi-year license contracts, is included in "Accounts receivable, net" on the unaudited condensed consolidated balance sheet.

*Contract Assets* 

Contract assets arise when revenue is recognized prior to billing customers and payment is contingent upon a future event, other than the passage of time. Contract assets primarily relate to the Company's rights to consideration under a long-term IP license agreement when the licenses have been transferred to the customers, but payment is conditional on factors other than the passage of time.

*Contract Liabilities*

Contract liabilities consist of deferred revenue, advanced payments and deposits from customers for goods and services that are yet to be provided. Deferred revenue includes billings in excess of revenue recognized related to product sales, licenses, extended warranty and other services revenue, and is recognized as revenue when the Company performs under the contract. The long-term portion of deferred revenue, mostly related to obligations under license arrangements and extended warranty, is classified as non-current contract liabilities and is included in other non-current liabilities in the Company's unaudited condensed consolidated balance sheets. Customer advanced payments represent required customer payments in advance of product shipments according to customer's payment term. Customer advance payments are recognized as revenue when control of the performance obligation is transferred to the customer. Customer deposits represent consideration received from a customer which can be applied to future product or service purchases, or refunded.

Contract assets and liabilities are presented net at the individual contract level in the unaudited condensed consolidated balance sheet and are classified as current or non-current based on the nature of the underlying contractual rights and obligations.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Contract assets, current | $1011 | $937 |
| Contract assets, non-current portion | 281 | 281 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total contract assets | $1292 | $1218 |
| Contract liabilities, current |  |  |
| &nbsp;&nbsp;Deferred revenues from multi-year licensing agreements | $133 | $133 |
| &nbsp;&nbsp;Other contract liabilities | 24026 | 20572 |
| Contract liabilities, non-current portion |  |  |
| &nbsp;&nbsp;Deferred revenues from multi-year licensing agreements | $391 | $429 |
| &nbsp;&nbsp;Other contract liabilities | 2560 | 2677 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total contract liabilities | $27110 | $23811 |

---

Deferred revenues from multi-year licensing agreements mainly represent minimum royalty payments received from licensees relating to long-term IP license agreements for which the Company has future obligations. Royalties from the IP license agreements are recognized at the later of the period the sales occur or the satisfaction of the performance obligations to which some or all of the royalties have been allocated.

Other contract liabilities primarily relate to a multi-year contract entered in 2023 with a customer to sell the Company's products. During the three months ended March 31, 2026, the Company recognized no revenue associated with this contract. As of March 31, 2026, $12.5 million remained deferred until a future product delivery date.

The following table provides information about contract liabilities (remaining performance obligations) and the significant changes in the balances (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Beginning balance | $23811 | $36889 |
| Net revenue deferred in the period | 1730 | 587 |
| Contract liabilities acquired in the Stereolabs acquisition | 2279 |  |
| Revenue recognized that was included in the contract liability balance at the beginning of the period | (710) | (7103) |
| Ending balance | $27110 | $30373 |

---

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Note 13. Segment**

The Company's chief operating decision maker ("CODM") is the Chief Executive Officer. The Chief Executive Officer reviews financial information including revenue, expenses and net loss presented on a consolidated basis, accompanied by certain supplemental information about significant expense categories for purposes of allocating resources and evaluating the Company's financial performance. The Company operates as one reportable and operating segment, which relates to the sale and production of lidar sensors, cameras and AI compute systems and there are no segment managers who are held accountable for operations, operating results and plans for levels or components below the consolidated unit level. The CODM assesses financial performance of the reportable segment and decides how to allocate resources based on the net loss that also is reported as the net loss attributable to the Company on the unaudited condensed consolidated statements of operations. The net loss is also used by our CODM to monitor actual results versus budget and prior periods amounts of our reportable segment and decide how to expand business or to return value to shareholders. The measure of the segment assets is reported on the unaudited condensed consolidated balance sheet as total assets.

The following table reflects the significant expenses of our reportable segment (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Total revenue | $48578 | $32632 |
| Less<sup>(1)</sup>: |  |  |
| Product manufacturing costs | 22499 | 15731 |
| Stock based compensation and amortization expense | 1689 | 1593 |
| Other costs<sup>(2)</sup> | 3552 | 1825 |
| Research and development | 16082 | 14985 |
| Sales and marketing | 7840 | 6423 |
| General and administrative | 16128 | 15905 |
| Total other income, net | (2299) | (2008) |
| Provision for income tax expense | 552 | 195 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(17465) | $(22017) |

---

<sup>(1)</sup> The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.

<sup>(2)</sup> Other costs primarily includes inventory excess and obsolescence, scrap, warranty, freight and other cost of revenue items.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis of our results of operations and financial condition of Ouster, Inc. ("we," "us," "our," the "Company," "Ouster") should be read together with the information set forth in our unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report, as well as our audited consolidated financial statements and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in Ouster's Annual Report on Form 10-K (the "2025 Annual Report") filed with the SEC on March 2, 2026. This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties, including with respect to the potential future impact of tariffs and other trade measures on the Company's business and results of operations. Ouster's actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled "Risk Factors" in Ouster's 2025 Annual Report and as may be further updated from time to time in the Company's other filings with the SEC. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.*

**Overview** 

Ouster was founded in 2015 with the invention of its high-performance digital lidar and is headquartered in San Francisco, California. We are a leader in sensing and perception for Physical AI across industrial, robotics, automotive, and smart infrastructure. With a unified platform of high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and AI models, Ouster delivers solutions that improve quality of life by enabling machines to sense, think, act, and learn in the physical world. To grow our business, we have introduced new product lines and made several acquisitions to accelerate growth. We continue to invest in growing our hardware product portfolio, increasing the capabilities of our software solutions, and opportunistically expanding our sales and marketing efforts.

We are a leading global provider of lidar sensors and solutions. We design and manufacture high-resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets, which allows each to understand and visualize the surrounding world and enable safe operation and autonomy. We believe our sensors are one of the highest-performing, lowest-cost lidar solutions available today.

We believe that our extensive patent coverage creates material barriers to entry.

**Products and Solutions**

In addition, our portfolio has expanded to include Stereolabs's growing product line, which now includes the ZED X, ZED X Mini, and ZED X Nano stereo cameras, the ZED X One monocular camera, and the ZED Box edge compute. We are currently developing our solid-state digital flash ("DF") sensors, which is a suite of short, mid, and long-range solid-state digital lidar sensors that provide uniform precision imaging without motion blur across an entire field of view.

Ouster provides Physical AI solutions tailored for smart infrastructure applications. Our software solutions, built on proprietary AI models, enable real-time people and object detection, classification, and tracking for actionable, intuitive, and customizable insights while preserving personally identifiable information. Ouster Gemini is our digital lidar powered perception platform designed for security and crowd analytics, logistics, and intelligent transportation systems. Ouster BlueCity is our turnkey real-time traffic management solution for analytics and signal actuation to improve traffic flow, road safety, and urban planning.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Factors Affecting Our Performance** 

*Commercialization of Lidar Applications.* We believe that our lidar solutions are approaching an inflection point of adoption across our target end market applications and that we are well-positioned to capitalize on this market adoption. However, as our customers continue research and development projects that rely on lidar technology, it is difficult to estimate the timing of ultimate end market and customer adoption. As a result, we expect that our results of operations, including revenue and gross margins, will improve over time but may fluctuate on a quarterly and annual basis for the foreseeable future. As the market for lidar solutions matures and more customers reach a commercialization phase with solutions that rely on our technology, the fluctuations in our operating results may become less pronounced. Our strategic business objectives also include growing the software-attached business, transforming the product portfolio, and executing towards profitability.

*Number of Customers in Production.* For certain strategic customers and markets, our products must be integrated into a broader platform, which then must be tested and validated to achieve system-level performance and reliability thresholds that enable commercial production and sales. The time necessary to reach commercial production varies from six months to several years, based on the market and application. For example, the production cycle in the automotive market tends to be substantially longer than in our other target markets. It is critical to our future success in each of our target end markets that our customers reach commercial production and select our products in their commercial production applications, and that we avoid unexpected cancellations of major purchases of our products. Because the timelines to reach production vary significantly and the revenue generated by each customer in connection with commercial production is unpredictable, it is difficult for us to reliably predict our financial performance.

*Customers' Sales Volumes.* Our customer base is diversified, and we aim to continue to penetrate diverse end markets to increase our sales volumes. Ultimately, widespread adoption of our customers' products that incorporate our lidar solutions will depend on many factors, including the size of our customers' end markets, market penetration of our customers' products that incorporate our digital lidar solutions, our customers' ability to sell their products, and the financial stability and reputation of our customers.

*Average Selling Prices ("ASPs"), Product Costs and Margins.* Our product costs and gross margins depend largely on the volumes of sensors shipped, the mix of existing and new products sold and the number and variety of solutions we provide to our customers. We expect that our selling prices will vary by target end market and application due to market-specific supply and demand dynamics. We expect to continue to experience some downward pressure on prices from signing anticipated large multi-year agreements in the near term with multi-year negotiated pricing. We expect that these customer-specific selling price fluctuations combined with our volume-driven product costs may drive fluctuations in revenue and gross margins on a quarterly basis. In addition, we expect that the current uncertainty surrounding U.S. trade relationships may impact our future product costs and margins, particularly to the extent there are significant tariffs or trade restrictions imposed on goods imported from Thailand, Canada, Taiwan or China that are used in our products. Although we are taking steps to mitigate the impacts of potential tariffs, we do not expect to be able to offset or avoid such costs in full. In addition, our contractual arrangements generally provide that our customers will pay the costs of tariffs. These costs could impact customer demand and adoption as described above under "Customers' Sales Volumes."

*Continued Investment and Innovation.* We believe that we are a leading lidar provider. Our financial performance is significantly dependent on our ability to maintain this leading position, which is further dependent on the investments we make in research and development. We believe it is essential that we continue to identify and respond to rapidly evolving customer requirements, including successfully progressing our digital lidar roadmap and developing technologies that will enhance the operating performance of our products. We announced our Rev8 family of products. Our "Chronos" chip has been fabricated by our foundry partner and is now undergoing in-house testing. If we fail to continue our innovation, our market position and revenue may be adversely affected, and our investments in that area will not be recovered.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

*Supply Chain Continuity.* Some of the key components in the products we have designed or are currently designing come from limited or single source suppliers. If these third parties experience financial, operational, manufacturing capacity or other difficulties, or experience shortages in required components, or if they are otherwise unable or unwilling to continue to manufacture these components in required volumes or at all, our supply may be disrupted or be on less favorable terms. For example, we may be required to seek alternate manufacturers or suppliers for our products. It would be time-consuming, and could be costly and impracticable, to begin to use and qualify new manufacturers, components or designs, and such changes could cause significant interruptions in supply and could have an adverse effect on our ability to meet our scheduled product deliveries and may subsequently lead to the loss of sales. In addition, we are monitoring impact of the recent tariff and trade policy actions taken by the United States and foreign governments on our supply chain. We are considering ways to mitigate the impact of these tariff and trade policy actions and the uncertainties arising from the rapidly changing global trade environment on our supply chain; however, there can be no assurances that such mitigation efforts will be successful.

*Market Trends and Uncertainties.* We anticipate increasing demand for our digital lidar solution. We estimate a multi-billion dollar total addressable market ("TAM") for our solutions in the future. We define our TAM as applications in the automotive, industrial, robotics, and smart infrastructure end markets where we actively engage and maintain customer relationships. Each of our target markets is potentially a significant global opportunity, and these markets have historically been underserved by limited or inferior technology or not served at all. We believe we are well-positioned in our market as a leading provider of high-resolution lidar sensors.

We may not be able to take advantage of demand if we are unable to anticipate regulatory changes and adapt quickly enough to meet such new regulatory standards or requirements applicable to us or to our customers' products in which our lidar sensors are used. Market acceptance of lidar technology and active safety technology depend upon many factors, including cost, performance, safety performance, regulatory requirements and international taxes or tariff and trade policy actions of governments related to such technologies. These factors may impact the ultimate market acceptance of our lidar technology.

*International Expansion.* We view international expansion as an important element of our strategy to increase revenue and achieve profitability. We continue to position ourselves in geographic markets that we expect to serve as important sources of future growth. We have an existing presence in three regions: Americas; Asia and Pacific; and Europe, Middle East and Africa. We intend to expand our presence in these regions over time including through distribution partnerships. Expanded global reach will require continued investment and may expose us to additional foreign currency risk, international taxes, tariff and trade policy actions of foreign governments, legal obligations, geopolitical conflict, including war in the Middle East, export/import regulations and additional operational costs. These risks and challenges may impact our ability to meet our projected sales volumes, revenues, and gross margins. In addition, the current uncertainty surrounding U.S. trade relationships may impact our future international sales, particularly to the extent there are significant tariffs or trade restrictions imposed on goods imported from the United States.

**Components of Results of Operations** 

***Revenue***

The majority of our revenue comes from the sale of our lidar sensors, cameras, and AI compute systems both directly to end users and through distributors both domestically and internationally. We recognize revenue from product sales when the performance obligation of transferring control of the product to the customer has been met, generally when the product is shipped. We also recognize revenue by performing services or obligations related to product development, validation, IP license agreements, maintenance under our extended warranty contracts, and shipping. We do not expect these services to be material components of revenue, cost of revenue or gross margin in the near future. Performance obligations related to services are generally recognized over time, based on cost-to-cost input basis or straight-line over time. Amounts billed to customers related to shipping and handling are classified as revenue, and we have elected to recognize the cost of shipping activities that occur after control has transferred to the customer as a fulfillment cost rather than a separate performance obligation. All related costs are accrued and recognized within cost of revenue when the related revenue is recognized.

Most of our customers are innovators and early technology adopters incorporating our products into their solutions. Currently, our product revenue consists of both customers ordering small volumes of our products that are in an evaluation phase and customers that order larger volumes of our products and have more predictable long-term production schedules. However, we believe we are still at the very beginning of the adoption curve, and some customers are still learning their growth and demand rates which can impact the timing of purchase orders quarter to quarter. As we grow our business, we expect to continue to improve our own understanding of our customers' needs and timelines, and expect the timing of orders will have a less notable impact on our quarterly results.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Cost of Revenue***

Cost of revenue consists of the manufacturing cost components, personnel-related expenses, including salaries, benefits, and stock-based compensation directly associated with our manufacturing organization, and amounts paid to our third-party contract manufacturer and vendors. Our cost of revenue also includes depreciation of manufacturing equipment, amortization of intangible assets, an allocated portion of overhead, facility and information technology ("IT") costs, warranty expenses, excess and obsolete inventory, tariffs, shipping costs and merchant fees.

***Gross Profit and Gross Margin***

Our gross profit equals total revenues less our total cost of revenues, and our gross margin is our gross profit expressed as a percentage of total revenue. Our gross margin is subject to quarterly fluctuations in product mix, price and volume.

***Operating Expenses***

*Research and Development Expenses* 

Research and development ("R&D") activities are primarily conducted at our San Francisco headquarters and our additional R&D facilities in France, Scotland and Canada and consist of the following activities:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Design, prototyping, and testing of proprietary electrical, optical, and mechanical subsystems for our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Robust testing for safety certifications;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Development of new products and enhancements to existing products in response to customer requirements including firmware and software development of lidar and camera integration products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Custom SoC design for Ouster's digital lidar products; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Development of custom manufacturing equipment.

R&D expenses consist of personnel-related expenses, including salaries, benefits, and stock-based compensation, for all personnel directly involved in R&D activities, third-party engineering and contractor costs, prototype expenses, amortization of intangible assets, and an allocated portion of overhead, facility and information technology ("IT") costs that support R&D activities.

R&D costs are expensed as they are incurred. Our investment in R&D will continue to grow as we invest in new lidar technology and related software. Our absolute amount of R&D expenses is expected to grow over time; however, we expect R&D as a percentage of revenue to decrease as our business grows.

*Sales and Marketing Expenses* 

Our business development, customer support and marketing teams are located in offices worldwide. Selling and marketing expenses consist of personnel-related expenses, including salaries, commissions, benefits, and stock-based compensation, for all personnel directly involved in business development, customer support, and marketing activities, and marketing expenses including trade shows, advertising, and demonstration equipment. Sales and marketing expenses also include amortization expense of intangible assets related to customer relationships and a trade name associated with the acquisitions and an allocated portion of facility and IT costs that support sales and marketing activities. We expect sales and marketing expenses as a percentage of revenue to decrease over time as our business grows.

*General and Administrative Expenses* 

General and administrative expenses consist of personnel-related expenses, including salaries, benefits, and stock-based compensation, of our executives and members of the board of directors, finance, human resources, an allocated portion of facility and IT costs that support general and administrative activities, as well as amortization of intangible assets, legal fees, patent prosecution, accounting, finance and professional services, as well as insurance and bank fees. We have experienced and may in the near-term experience additional increases in general and administrative expenses related to legal, accounting, finance and professional services costs associated with acquisition-related transaction and integration costs, litigation activities, hiring more personnel and consultants to support our international expansion and compliance with the applicable provisions of the Sarbanes-Oxley Act and other SEC rules and regulations as a result of being a public company. Our absolute amount of general and administrative expenses will grow over time; however, we expect general and administrative expenses as a percentage of revenue to decrease as our business grows.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Interest Income and Other Income (Expense), Net***

Interest income consists primarily of income earned on our cash and cash equivalents and short-term investments. These amounts will vary based on our respective balances and market rates. Other income (expense), net consists primarily of change in fair value with foreign currency forward contracts, realized and unrealized gains and losses on foreign currency transactions and balances, realized gains and losses related to sales of our available-for-sale investments.

***Income Taxes***

Our income tax provision consists of federal, state and foreign current and deferred income taxes. Our income tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items arising in the quarter. Our effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on deferred tax assets as it is more likely than not that some, or all, of our deferred tax assets will not be realized. We continue to maintain a full valuation allowance against our U.S. Federal, state and certain foreign deferred tax assets, excluding specific balances due to the Stereolabs acquisition. The Company's income tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items arising in the quarter. The tax provision for the three months ended March 31, 2026 was $0.6 million, which includes $0.9 million of discrete items primarily related to withholding taxes on sales to customers. Our income tax expense for the three months ended March 31, 2025 was not material to our unaudited condensed consolidated financial statements.

**Results of Operations:** 

The results of operations presented below should be reviewed in conjunction with the unaudited condensed consolidated financial statements and notes included elsewhere in this Quarterly Report. The following table sets forth our unaudited condensed consolidated results of operations data for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | **(dollars in thousands)** | **(dollars in thousands)** |
| Revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product revenue | $48231 | $31105 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties | 347 | 1527 |
| Total revenue | 48578 | 32632 |
| Cost of revenue<sup>(1)</sup> | 27740 | 19149 |
| Gross profit | 20838 | 13483 |
| Operating expenses<sup>(1)</sup>: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 16082 | 14985 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 7840 | 6423 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 16128 | 15905 |
| Total operating expenses | 40050 | 37313 |
| Loss from operations | (19212) | (23830) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 2474 | 1705 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | (175) | 303 |
| Total other income, net | 2299 | 2008 |
| Loss before income taxes | (16913) | (21822) |
| Provision for income tax expense | 552 | 195 |
| Net loss | $(17465) | $(22017) |

---

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

The following table sets forth the components of our unaudited condensed consolidated statements of operations and comprehensive loss data as a percentage of total revenue for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | **(% of total revenue)** | **(% of total revenue)** |
| Revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product revenue | 99% | 95% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties | 1 | 5 |
| Total revenue | 100 | 100 |
| Cost of revenue<sup>(1)</sup> | 57 | 59 |
| Gross profit | 43 | 41 |
| Operating expenses <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 33 | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 16 | 20 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 33 | 49 |
| Total operating expenses | 82 | 114 |
| Loss from operations | (39) | (73) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 5 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net |  | 1 |
| Total other income, net | 5 | 6 |
| Loss before income taxes | (34) | (67) |
| Provision for income tax expense | 1 | 1 |
| Net loss | (35)% | (68)% |

---

<sup>(1)</sup> Includes stock-based compensation expense as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | **(in thousands)** | **(in thousands)** |
| Cost of revenue | $826 | $1137 |
| Research and development | 2616 | 4305 |
| Sales and marketing | 766 | 1106 |
| General and administrative | 3286 | 1950 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation | $7494 | $8498 |

---

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Comparison of the three months ended March 31, 2026 and 2025**

***Revenue***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Change** |
| | **2026** | **2025** | $**%** |
| | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Revenue by geographic location: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Americas | $32798 | $15528 | 111% |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia and Pacific | 7990 | 12464 | (36) |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, Middle East and Africa | 7790 | 4640 | 68 |
| Total | $48578 | $32632 | 49% |

---

*Revenue*

Revenue increased by $15.9 million or 49%, to $48.6 million for the three months ended March 31, 2026 from $32.6 million for the comparable period in the prior year. The increase in revenue was primarily driven by increased sensor volumes as customers increased their purchase levels compared to the prior year period.

We recorded $0.3 million and $1.5 million, respectively in patent royalty revenue for the three months ended March 31, 2026 and three months ended March 31, 2025.

***Cost of Revenue***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Change** |
| | **2026** | **2025** | $**%** |
| | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| &nbsp;&nbsp;Cost of revenue | $27740 | $19149 | 45% |

---

Cost of revenue increased by $8.6 million, or 45%, to $27.7 million for the three months ended March 31, 2026 from $19.1 million for the comparable period in the prior year. The increase in cost of revenue was primarily attributable to higher product manufacturing costs, the inclusion of manufacturing costs from our recently-acquired subsidiary, Stereolabs, higher amortization costs from acquired intangible assets and tariffs.

Gross margin rose to 43% for the three months ended March 31, 2026 from 41% in the prior year period primarily due to increased sensor volumes, offset in part by lower ASPs and the inclusion of production costs from our recently-acquired subsidiary, Stereolabs.

***Operating Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Change** |
| | **2026** | **2025** | $**%** |
| | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Operating expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | $16082 | $14985 | 7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 7840 | 6423 | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 16128 | 15905 | 1 |
| Total operating expenses | $40050 | $37313 | 7% |

---

*Research and Development* 

Research and development expenses increased by $1.1 million, or 7%, to $16.1 million for the three months ended March 31, 2026 from $15.0 million for the comparable period in the prior year. The increase was primarily attributable to the inclusion of Stereolabs and the increase in compensation expenses for employees engaged in research and product development function.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

*Sales and Marketing* 

Sales and marketing expenses increased by $1.4 million, or 22%, to $7.8 million for the three months ended March 31, 2026 from $6.4 million for the comparable period in the prior year. The increase was primarily attributable to the inclusion of Stereolabs and the increase in the amortization of acquisition-related intangible assets.

*General and Administrative*

General and administrative expenses increased by $0.2 million, or 1%, to $16.1 million for the three months ended March 31, 2026 from $15.9 million for the comparable period in the prior year. The increase was primarily attributable to transaction and integration costs associated with the Stereolabs acquisition, offset in part by lower litigation and settlement activities.

***Interest Income and Other Expense, Net***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Change** |
| | **2026** | **2025** | $**%** |
| | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Interest income | $2474 | $1705 | 45% |
| Other income (expense), net | (175) | 303 | (158) |
| Total interest income and other income (expense), net | $2299 | $2008 | 14 |

---

The year-over-year increase in interest income was due primarily to $0.6 million in interest income earned on an IRS income tax refund received during the three months ended March 31, 2026.

Other income (expense), net was not material for the three months ended March 31, 2026 and 2025.

***Income Taxes***

We were subject to income taxes in the United States and miscellaneous foreign jurisdictions for the three months ended March 31, 2026 and 2025. The Company's income tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items arising in the quarter. The tax provision for the three months ended March 31, 2026 was $0.6 million, which includes $0.9 million of discrete items primarily related to withholding taxes on sales to customers. Our income tax expense for the three months ended March 31, 2025 was not material to our unaudited condensed consolidated financial statements.

**Liquidity and Capital Resources** 

Our principal sources of liquidity are our cash and cash equivalents and short-term investments, cash generated from sales of our products, and sales of common stock under our at-the market equity offering program.

Our primary requirements for liquidity and capital are to finance working capital, inventory management, capital expenditures and general corporate purposes. We expect these needs to continue as we develop and grow our business.

As of March 31, 2026, we had an accumulated deficit of $990.9 million and cash, cash equivalents, restricted cash and short-term investments of $174.9 million. Management believes that our existing sources of liquidity will be sufficient to fund our operations for at least twelve months from the date of this Quarterly Report. However, we may need to raise, or may choose to raise additional capital in the future to support our operations.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

We manage our cash and cash equivalents with financial institutions that we believe have high credit quality and, at times, such amounts exceed federally insured limits. The failure of any bank with which we maintain a commercial relationship could cause us to lose our deposits in excess of the federally insured or protected amounts. We have experienced recurring losses from operations, and negative cash flows from operations, and we expect to continue operating at a loss and to have negative cash flows from operations for the foreseeable future. Because we are in the growth stage of our business and operate in an emerging field of technology, we expect to continue to invest in research and development and opportunistically expand our sales and marketing teams worldwide. We may require additional capital to respond to technological advancements, competitive dynamics or technologies, customer demands, business opportunities, challenges, acquisitions, or unforeseen circumstances and in either the short-term or long-term may determine to engage in equity or debt financings, or may choose to raise additional capital opportunistically if we believe market conditions are favorable. If we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited. In particular, current macroeconomic conditions, including elevated inflation rates and high interest rates, have resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital. If we are unable to raise additional funds when or on the terms desired, our business, financial condition and results of operations could be adversely affected.

***ATM Agreement***

On May 12, 2025, we entered into an At Market Issuance Sales Agreement (the "ATM Agreement") with Oppenheimer & Co. Inc., pursuant to which the Company may offer and sell, from time to time, through or to the agent, acting as agent or principal, shares of the Company's common stock, having an aggregate offering price of up to $100.0 million.

From the date of the inception of the ATM Agreement to March 31, 2026, the Company sold 4,671,406 shares at a weighted-average sales price of $20.88 per share under the ATM Agreement, resulting in cumulative gross proceeds to the Company totaling approximately $97.5 million before deducting offering costs, sales commissions and fees. Cumulative net proceeds to the Company totaled approximately $95.6 million after deducting offering costs, sales commissions and fees. The Company plans to use the net proceeds from sales under the ATM Agreement for working capital and general corporate purposes.

During the three months ended March 31, 2026, no shares of common stock were sold under the ATM Agreement.

The remaining availability under the ATM Agreement as of March 31, 2026 is approximately $2.5 million.

***Material Cash Requirements***

We are a party to many contractual obligations involving commitments to make payments to third parties. These obligations impact our short-term and long-term liquidity and capital resource needs. Certain contractual obligations are reflected on the unaudited condensed consolidated balance sheet as of March 31, 2026, while others are considered future commitments. Our contractual obligations primarily consist of non-cancelable purchase commitments with various parties to purchase goods or services, primarily inventory, entered into in the normal course of business and operating leases. For information regarding our other contractual obligations, refer to Note 7. Commitments and Contingencies to our unaudited condensed consolidated financial statements included in this Quarterly Report as well as Note 7. Leases and Note. 8. Commitments and Contingencies Part II, Item 8 of our 2025 Annual Report.

***Cash Flow Summary***

The following table summarizes our cash flows from continuing operations for the periods presented:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | **(in thousands)** | **(in thousands)** |
| Net cash (used in) provided by: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $(7281) | $(4879) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities | $17063 | $12590 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities | $705 | $660 |

---

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

***Operating Activities***

During the three months ended March 31, 2026, operating activities used $7.3 million in cash. The primary factors affecting our operating cash flows during this period were our net loss of $17.5 million, offset by our non-cash charges of $10.8 million, primarily consisting of depreciation and amortization of $2.7 million, stock-based compensation of $7.5 million, amortization of right-of-use asset of $0.8 million offset by accretion on short-term investments of $0.5 million. The changes in our operating assets and liabilities of $0.6 million were primarily due to a decrease in accounts receivable of $6.5 million, increase in inventory of $3.7 million, an increase in prepaid expenses and other assets of $0.2 million, a decrease in accounts payable of $3.5 million, an increase in accrued and other liabilities of $0.1 million, an increase in contract liabilities of $1.0 million and decrease in operating lease liability of $0.9 million.

During the three months ended March 31, 2025, operating activities used $4.9 million in cash. The primary factors affecting our operating cash flows during this period were our net loss of $22.0 million, offset by our non-cash charges of $11.2 million, primarily consisting of depreciation and amortization of $1.8 million, stock-based compensation of $8.5 million, amortization of right-of-use asset of $1.2 million offset by accretion on short-term investments of $0.8 million. The changes in our operating assets and liabilities of $5.9 million were primarily due to a decrease in accounts receivable of $4.1 million, decrease in inventory of $1.1 million, an increase in prepaid expenses and other assets of $3.9 million, an increase in accounts payable of $4.1 million, an increase in accrued and other liabilities of $8.7 million, a decrease in contract liabilities of $6.5 million and decrease in operating lease liability of $1.7 million.

***Investing Activities***

During the three months ended March 31, 2026, cash provided by investing activities was $17.1 million, consisting primarily of $57.9 million in proceeds from the sale and maturities of short-term investments, offset in part by $10.8 million purchases of short-term investments and $27.5 million used for the acquisition of Stereolabs, net of cash acquired.

During the three months ended March 31, 2025, cash provided by investing activities was $12.6 million, consisting primarily of $27.0 million in proceeds from the sale and maturities of short-term investments, offset in part by $13.9 million of purchases of short-term investments.

***Financing Activities***

During both the three months ended March 31, 2026 and the three months ended March 31, 2025, cash provided by financing activities was $0.7 million, primarily due to proceeds received to fund employees tax obligation for vested RSUs.

**Critical Accounting Policies and Estimates** 

Our critical accounting estimates are described in Management's Discussion and Analysis of Financial Condition and Results of Operations in our 2025 Annual Report. There have been no significant changes to our critical accounting policies and estimates since the filing of our 2025 Annual Report.

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions. Certain of these policies require the application of subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. These estimates and assumptions are based on historical experience, changes in the business environment and other factors that we believe to be reasonable under the circumstances. Different estimates that could have been applied in the current period or changes in the accounting estimates that are reasonably likely can result in a material impact on our financial condition and operating results in the current and future periods.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates, foreign currency exchange rates and to a lesser extent, inflation risk. The following analysis provides quantitative and qualitative information regarding these risks.

***Inflation Risk***

General inflation in the U.S., Europe and other geographies has risen significantly in recent years. To date, we do not believe that inflation has had a material effect on our business, financial condition, or results of operations, other than its impact on the general economy. However, we are monitoring the current inflationary environment, particularly as it may be impacted by proposed and/or newly implemented tariffs. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases, and our inability or failure to do so could harm our business, financial condition and results of operations.

***Interest Rate Risk***

As of March 31, 2026, we had cash and cash equivalents, restricted cash and short-term investments of $174.9 million, of which $60.4 million consisted of institutional money market funds, $30.4 million consisted of commercial paper, and $64.0 million consisted of corporate debt securities, all of which carries a degree of interest rate risk. The primary goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes.

These investments are subject to interest rate risk, as sharp increases in market interest rates could have an adverse impact on their fair value. Although the fair values of these instruments can fluctuate, we believe that the short-term, highly liquid nature of these investments, and our ability to hold these instruments to maturity, reduces our risk for potential material losses. A hypothetical 100 basis point change in interest rates would not have a material impact on our financial condition or results of operations due to the short-term nature of our investment portfolio.

As of March 31, 2026, we had no debt outstanding and therefore are not exposed to interest rate risk with respect to debt.

***Foreign Currency Exchange Risk***

Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. Substantially all of our revenue is generated in U.S. dollars. Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the U.S. and to a lesser extent in Asia and Europe.

Our recently-acquired subsidiary, Stereolabs, is exposed to foreign currency risk primarily related to forecasted Euro-denominated operating expenditures and assets and liabilities denominated primarily in the Euro. Accordingly, our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. To mitigate these exposures, Stereolabs enters into forward foreign currency contracts to hedge the gains and losses generated by the re-measurement of certain recorded assets and liabilities in a non-functional currency and to offset certain operational exposures resulting from changes in foreign currency exchange rates. For the three months ended March 31, 2026, we recognized an unrealized loss on foreign currency forward contracts of $0.1 million in loss on undesignated derivatives in the condensed consolidated statements of operations.

The effect of a hypothetical 10% change in foreign currency exchange rates applicable to our business would not have a material impact on our historical consolidated financial statements.

As our international operations grow, we will continue to reassess our approach to managing our risk relating to fluctuations in currency rates. However, no strategy can completely insulate us from risks associated with such fluctuations and our currency exchange rate risk management activities could expose us to substantial losses if such rates move materially differently from our expectations.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Item 4. Controls and Procedures** 

***Limitations on Effectiveness of Controls and Procedures***

Disclosure controls and procedures include controls and other procedures that are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, ("Exchange Act") is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management of the Company, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

***Evaluation of Disclosure Controls and Procedures***

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2026. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2026.

***Changes in Internal Control over Financial Reporting***

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

We are, from time to time, party to various claims and legal proceedings arising in the ordinary course of our business. See Note 7. Commitments and Contingencies to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for a discussion of material legal proceedings.

**Item 1A. Risk Factors**

Investing in our securities involves a high degree of risk. You should carefully consider the risks described under the heading "Risk Factors" in Part I, Item 1A. of our 2025 Annual Report, the other information in this Quarterly Report, including our unaudited condensed consolidated financial statements and the related notes, as well as our other public filings with the SEC, before deciding to invest in our securities. There have been no material changes to the Company's risk factors previously disclosed in our 2025 Annual Report. The occurrence of any of the events described therein could harm our business, financial condition, results of operations, liquidity or prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

***(a) Disclosure in lieu of reporting on a Current Report on Form 8-K.***

None.

***(b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.*** 

None.

***(c) Insider trading arrangements and policies.***

During the three months ended March 31, 2026, no director or officer of the Company, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**Item 6. Exhibits.** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit Number** | **Description** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| | | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Filed/ Furnished herewith** |
| <u>[3.1](https://www.sec.gov/Archives/edgar/data/0001816581/000119312521076326/d149743dex31.htm)</u> | <u>[Certificate of Incorporation of Ouster, Inc.](https://www.sec.gov/Archives/edgar/data/0001816581/000119312521076326/d149743dex31.htm)</u> | S-4 POS | 333-251611 | 3.1 | 3/10/2021 |  |
| <u>[3.2](https://www.sec.gov/Archives/edgar/data/1816581/000119312523108331/d502108dex31.htm)</u> | <u>[Certificate of Amendment to Certificate of Incorporation of Ouster, Inc.](https://www.sec.gov/Archives/edgar/data/1816581/000119312523108331/d502108dex31.htm)</u> | 8-K | 001-39463 | 3.1 | 4/20/2023 |  |
| <u>[3.3](https://www.sec.gov/Archives/edgar/data/1816581/000119312524103286/d813445dex31.htm)</u> | <u>[Second Amended and Restated Bylaws of Ouster, Inc. (effective as of April 18, 2024)](https://www.sec.gov/Archives/edgar/data/1816581/000119312524103286/d813445dex31.htm)</u> | 8-K | 001-39463 | 3.1 | 4/22/2024 |  |
| <u>[4.1](https://www.sec.gov/Archives/edgar/data/1745317/000119312522029612/d54842dex41.htm)</u> | <u>[Warrant to Purchase Common Stock of Velodyne Lidar, Inc., by and between Velodyne Lidar, Inc. and Amazon.com NV Investment Holdings LLC, dated as of February 4, 2022](https://www.sec.gov/Archives/edgar/data/1745317/000119312522029612/d54842dex41.htm)</u> | 8-K | 001-38703 | 4.1 | 2/7/2022 |  |
| <u>[31.1](oust-31mar26xex311.htm)</u> | <u>[Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended](oust-31mar26xex311.htm)</u> |  |  |  |  | \* |
| <u>[31.2](oust-31mar26xex312.htm)</u> | <u>[Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended](oust-31mar26xex312.htm)</u> |  |  |  |  | \* |
| <u>[32.1](oust-31mar26xex321.htm)</u> | <u>[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](oust-31mar26xex321.htm)</u> |  |  |  |  | \*\* |
| <u>[32.2](oust-31mar26xex322.htm)</u> | <u>[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](oust-31mar26xex322.htm)</u> |  |  |  |  | \*\* |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  | \* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  | \* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  | \* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  | \* |
| 101.LAB | Inline XBRL Taxonomy Label Linkbase Document |  |  |  |  | \* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  | \* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |  |  |  |  | \* |

---

____________

\* Filed herewith. <br> \*\* Furnished herewith.

------

<u>[**Table of Contents**](#i105426b996a349fab16c7184348567c3_7)</u>

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | Ouster, Inc. | Ouster, Inc. |
| Date: May 5, 2026 | By: | /s/ Kenneth P. Gianella |
|  | Name: | Kenneth P. Gianella |
|  | Title: | Chief Financial Officer (*principal financial officer and principal accounting officer*) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION** 

I, Angus Pacala, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Ouster, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

------

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 5, 2026 | By: | /s/ Angus Pacala |
|  |  | Angus Pacala |
|  |  | Co-Founder and Chief Executive Officer <br>*(principal executive officer)* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION** 

I, Kenneth Gianella, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Ouster, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

------

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 5, 2026 | By: | /s/ Kenneth P. Gianella |
|  |  | Kenneth P. Gianella |
|  |  | Chief Financial Officer<br>*(principal financial officer)* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Ouster, Inc. (the "Company") for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: May 5, 2026 | By: | /s/ Angus Pacala |
|  |  | Angus Pacala |
|  |  | Co-Founder and Chief Executive Officer <br>(*principal executive officer*) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Ouster, Inc. (the "Company") for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: May 5, 2026 | By: | /s/ Kenneth P. Gianella |
|  |  | Kenneth P. Gianella |
|  |  | Chief Financial Officer<br>(*principal financial officer)* |

---

<br>